Otsuka and Lundbeck announced that the Food and Drug Administration (FDA) has approved Abilify Maintena (aripiprazole) for extended-release injectable suspension as a prefilled dual-chamber syringe.

Abilify Maintena is an intramuscular injection indicated for the treatment of schizophrenia. The current Maintena Kit includes a vial of the lyophilized powder, diluent, and supplies. The new dual-chamber syringe will allow healthcare providers more flexibility with administration during patient office visits.

RELATED: Schizophrenia Deemed Group of Eight Separate Disorders

The mechanism of action of aripiprazole, an atypical antipsychotic, in the treatment of schizophrenia is unknown. However, the efficacy of aripiprazole may be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

The dual-chamber syringe will be available in 300mg and 400mg dosage strengths. It is expected to launch in January 2015.

For more information call (800) 438-9927 or visit